G-N 2 Cellular and Molecular Neurobiology

The objective of the Cellular & Molecular Neurobiology (CMN) research group at the IGTP is to foster basic and translational research in the stroke field. Our goal is to generate knowledge, test it into preclinical models of stroke and translate it to the clinical arena in order to provide a better life for stroke patients.

The group forms part of the larger group Vascular Pathologies of the Brain, led by Dr A Dàvalos in the Department of Neuroscience at the Germans Trias i Pujol Hospital on the Can Ruti Campus.  The Cellular & Molecular Neurobiology Group is led by Teresa Gassull.

Research lines

New generation therapies to protect the brain after stroke

  • As a result of our research, apotransferrin, a protein naturally present in the blood, is being developed as a new therapy for stroke. To date, we have obtained positive preclinical results in different experimental stroke models. This line of research was one of the finalist projects in the Bioemprendedor/Bioentrepreneur XXI 2014 Programme, and is at present recipient of a grant from the CaixaImpulse Programme 2015.
  • In an experimental stroke model, we have recently identified a novel candidate for the treatment of stroke that exerts actions at the frontier of neuroproteccion and neurorepair.
  • A proteomic approach in in vitro studies has identified novel potential target candidates downstream the N-methyl-D-aspartate (NMDA) receptor. Its potential to prevent stroke damage is currently being further evaluated using in vivo preclinical studies.

Biomarkers for successful and differential diagnosis of stroke subtypes and personalized therapy

  • We have recently found a biomarker that is increased in the blood of ischemic stroke patients at admission. Specific posttranslational modifications of this and other biomarkers are being reexamined to reach an improved specificity and sensitivity to diagnose stroke subtypes, ischemic or hemorrhagic. 
  • Blood biomarkers are under evaluation to personalize and improve the therapeutic benefit of apotransferrin in selected stroke patients.

In vivo molecular bioimaging to assess pathological hallmarks of stroke

  • In vivo molecular imaging of apoptosis, inflammation, BBB disruption, and homing of traceable adoptive cells in the brain ischemic areas are used to assess pathological hallmarks after experimental stroke.

More information

Contact

Teresa Gasull Dalmau, Principal Investigator

(+34) 93 497 86 85

tgasull(ELIMINAR)@igtp.cat